Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
Department of Medicine, Birmingham Veterans Affairs (VA) Medical Center, Birmingham, AL, United States.
Front Cell Infect Microbiol. 2021 Sep 6;11:732223. doi: 10.3389/fcimb.2021.732223. eCollection 2021.
In many ways, fungal diseases are forgotten or neglected. Given the significantly lower frequency compared to similar bacterial etiologies across the spectrum of infectious syndromes, it makes sense that anti-bacterial agents have seen the bulk of development in recent decades. The vast majority of new antifungal medications approved for use in the past 10 years have been new versions in the same class as existing agents. Clinical mycology is crying out for new mechanisms of action in the setting of rising resistance and emergence of new organisms. Fortunately, this trend appears to be reversing. There are numerous agents in advanced stages of development offering novel dosing regimens and mechanisms of action to combat these threats. Herein we review seven antifungal agents that we hope to see come to market in the coming years to aid physicians in the treatment of mucocutaneous and invasive fungal infections.
在许多方面，真菌感染都被忽视了。与感染综合征谱中类似的细菌病因相比，真菌的发病率要低得多，因此在过去几十年中，抗细菌药物的研发占据了主导地位。在过去 10 年中，批准用于临床的绝大多数新型抗真菌药物都属于现有药物的同类药物。在耐药性不断上升和新生物体不断出现的情况下，临床真菌学迫切需要新的作用机制。幸运的是，这种趋势似乎正在发生逆转。目前有许多处于研发后期的药物，它们提供了新的给药方案和作用机制，以应对这些威胁。在此，我们回顾了七种抗真菌药物，我们希望这些药物在未来几年能够上市，以帮助医生治疗黏膜和侵袭性真菌感染。
